$2 Share Price Not Far Fetched neither is $5 POSTING NEXT 3 POSTS TO DRIVE BASHERS CRAZY. SORRY IF YOU SOLD.
THEN I AM OUT OF THIS BOARD FOR A WHILE
$2 is only $500M Valuation. 2.5M test kits per month in sales at $5 USD = $12.5M USD/month. 50% margin = $6.25M USD X 12 month = $75M USD X 5 PE Ratio = $375M USD / $470M CAD ($2 Cad Stock). And on 10 PE Ratio = 750M USD / $940 CAD. ($4 CAD Stock) And that's only on 2.5M tests per month. Around a globe of 7B people and variants still rolling...and test -to treat measure being implemented with more spending.
I think THRM gets taken out when they start reaching 2.5M tests per month (as it validates the product) and then the bidding war begins. Boom! Then $5 is not that far from a potential, if not higher.